Mobio Interactive
  • Am Mindfulness
  • SCIENCE
  • Team
    • JOIN US
    • CEO
    • CTO
    • COC
    • Assistant to the CEO
    • Chief Commercial Officer
    • Lead Backend & Security
    • Product Designer
    • Clinical Trial Coordinator
    • AI Expert
    • Business Development Manager
    • Product Engineer
    • Unity Developer
    • Research Intern
  • Press
    • September 2, 2020
    • August 19, 2020
    • April 23, 2020
    • April 8, 2020
    • March 28, 2020
    • March 26, 2020
    • March 13, 2020
    • February 13, 2020
    • January 18, 2019
  • Contact

Cutting Edge Psychobiometrics.
​Rigorous Clinical Validation.

An Objective Measure of Stress at Scale

Using nothing more than the smartphone camera, Mobio Interactive's proprietary technology accurately and objectively measures stress in under 30 seconds.

Picture
We start with a colour scan of the face and pass the time series data from six different wavelengths of light into an algorithm that outputs heart rate (HR) and heart rate variability (HRV). This is possible because as your heart beats, your facial arteries dilate and contract in synchrony.
READ THE PUBLISHED RESULTS

Picture
We next send these HR and HRV data to a deep neural network that has been trained on thousands of individuals from all over the world, and this network then predicts - with remarkable accuracy - the level of stress that the data represent. Specifically, the AI is measuring the autonomic nervous system, which is what governs your "fight or flight" versus "rest and digest" modes.
READ THE PUBLISHED RESULTS

Picture
In addition, our app Am Mindfulness contains embedded tools that capture self-reported information, including a "stress slider" and "mood board". These in-app biomarkers have been benchmarked against medical questionnaires and are found to correlate with high significance.​
READ THE PUBLISHED RESULTS

Clinical Studies

Mobio Interactive rigorously interrogates the efficacy of our digital therapeutics.

Am Mindfulness is the first and only resilience app proven to outperform placebo.


Picture

Stress Resilience

In a landmark study, researchers found that MI's DTx produced "significant improvement" in stress resilience amongst university students self-reporting issues with anxiety, when compared to placebo.

READ THE LANDMARK Paper
Picture

Picture

Attentional Control

In landmark study, researchers found that MI's DTx produced "long-term benefits for attentional control," compared to placebo, indicating that MI's app Am Mindfulness can enhance focus in university students.
​
READ THE LANDMARK Paper
Picture

Picture

Psycho-oncology

In a clinical trial with urban and rural cancer survivors, Am Mindfulness provides stress reductions "similar in effect sizes of in-person programs," indicating medical-grade stress relief is now accessible to cancer patients regardless of their location.
READ THE STUDY PROTOCOL
Picture

Picture

Fear of Cancer Recurrence

In a clinical trial with cancer patients, researchers are investigating the potential for Am Mindfulness to reduce the "fear of cancer recurrence," something which is often a very serious burden on cancer survivors and their loved ones.
READ THE STUDY PROTOCOL
Picture

Picture

Physical Endurance

Researchers examined the effect of mental training with Am Mindfulness versus a control app on the total physical endurance of amature athletes.

​
PUBLISHED STUDY SOON
Picture

Picture

Mental Response to HIE

Researchers examined the mental response to HIE (High Intensity Exercise) in amature athletes who trained with Am Mindfulness versus a control app, and have found some intriguing results important for exercise paradigm adherence.
PUBLISHED STUDY SOON
Picture

Picture

Pain

Researchers are examining the potential for reducing the chronic pain experienced by cancer patients through the use of a VR product that Mobio Interactive has under development.
STUDY COMPLETES MAR., 2021
Picture

Picture

Quality of Life

Researchers are examining the potential for Am Mindfulness to improve psychological outcomes, as well as overall quality of life in patients with kidney cancer.
STUDY LAUNCHED NOV., 2020
Picture

Much of our ongoing research in patient populations is currently confidential, but we're committed to disseminating the results as soon as possible, for the benefit of patients as well as the entire DTx industry around the world.

Interested in conducting a trial? Let us know​.


Terms of Use
Privacy Policy
Toronto - Zurich - Shanghai - Singapore
​© 2020 Mobio Interactive PTE LTD
  • Am Mindfulness
  • SCIENCE
  • Team
    • JOIN US
    • CEO
    • CTO
    • COC
    • Assistant to the CEO
    • Chief Commercial Officer
    • Lead Backend & Security
    • Product Designer
    • Clinical Trial Coordinator
    • AI Expert
    • Business Development Manager
    • Product Engineer
    • Unity Developer
    • Research Intern
  • Press
    • September 2, 2020
    • August 19, 2020
    • April 23, 2020
    • April 8, 2020
    • March 28, 2020
    • March 26, 2020
    • March 13, 2020
    • February 13, 2020
    • January 18, 2019
  • Contact